308 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
29 May 24
Report of Foreign Private Issuer
7:05am
of the mechanism contributing to the very good safety profile that has been observed all along the clinical development in more than 1600 patients suffering … of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
13 May 24
Report of Foreign Private Issuer
7:03am
. This differential effect accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE … . These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
9 May 24
Report of Foreign Private Issuer
7:03am
and fibrosis, with an excellent safety profile. Currently Can-Fite is enrolling patients for a Phase IIb clinical study in Europe and in Israel … for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
6 May 24
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
7:11am
cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
About Can-Fite … third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
25 Apr 24
Current report (foreign)
7:03am
whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.
About Can-Fite … third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over
6-K
EX-99.1
d2g3o 00mvtgwbeg
15 Apr 24
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients
7:03am
6-K
EX-99.1
rksfp03g
3 Apr 24
Report of Foreign Private Issuer
7:07am
6-K
EX-99.1
2c8wr0o
28 Mar 24
Can-Fite Reports 2023 Financial Results and Clinical Update
7:05am
6-K
EX-99.1
k80lij5z8glexajec
11 Mar 24
Report of Foreign Private Issuer
7:27am
6-K
EX-99.1
apa4g1mtxb
28 Feb 24
Patent has already been issued in other major markets including the U.S., EU, Japan and China
7:06am
6-K
EX-99.1
klgek8mukzlr62lsh8no
30 Jan 24
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
7:24am
6-K
EX-99.1
gjr56zia blx7fdqty
29 Jan 24
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
7:05am
6-K
EX-99.1
cgp kuoo1lg
20 Dec 23
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
7:09am
6-K
EX-99.1
m7xwjg9ujw gwhrzkis
18 Dec 23
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
7:07am
6-K
EX-99.1
1coq ultsrak
4 Dec 23
Report of Foreign Private Issuer
7:05am
6-K
EX-99.1
n6r0jq 52gbvmbtx
30 Nov 23
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
7:05am
6-K
EX-99.1
blhy8ui22tw plnd9es
21 Nov 23
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
4:30pm
6-K
EX-99.1
gxqsb57 6oaa7l6t7vih
21 Nov 23
Report of Foreign Private Issuer
7:03am
6-K
EX-99.1
fb713wzj
1 Nov 23
Company management updates about ongoing activities and progress
7:05am